AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2019

Feb 20, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2018-09-28

Reporting Person: Alenson Carman (Principal Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-09-28	Common stock	S	152	$76.45	Disposed	0	Direct
2019-02-16	Common stock	M	790	—	Acquired	790	Direct
2019-02-19	Common stock	F	278	$58.03	Disposed	512	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-16	Restricted stock units	$	M	790	Disposed		Common stock (790)	Direct

Footnotes

F1: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.44 to $76.47. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F3: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.